Synthesis and biological evaluation of novel aromatic amide derivatives as potential BCR-ABL inhibitors

Bioorganic & Medicinal Chemistry Letters
2023.0

Abstract

BCR-ABL1 kinase is a key driver of the pathophysiology of chronic myeloid leukemia (CML). Current treatments need to broaden the chemical diversity of BCR-ABL1 kinase inhibitors to overcome drug resistance. We designed and synthesized a series of aromatic amide derivatives based on several generations of BCR-ABL1 kinase inhibitors. Biological studies showed that compared with Imatinib, these compounds showed significant proliferation inhibitory activities of HL-60 and K562 in cell activity assay. Compounds 4g and 4j exhibited significant anti-tumor activity against the K562 cells with IC<sub>50</sub> values of 6.03 ± 0.49 μM and 5.66 ± 2.06 μM respectively. Compounds 4g and 4j, as potential BCR-ABL1 inhibitors, inhibit the phosphorylation of ABL1 and CRKL in a dose-dependent manner. Therefore, compounds 4g and 4j can be used as a starting point for further optimization.

DOI： 10.1016/j.bmcl.2023.129144

Knowledge Graph

Similar Paper

Synthesis and biological evaluation of novel aromatic amide derivatives as potential BCR-ABL inhibitors
Bioorganic &amp; Medicinal Chemistry Letters 2023.0
Design, synthesis, and biological activity of 4-(imidazo[1,2- b ]pyridazin-3-yl)-1 H -pyrazol-1-yl-phenylbenzamide derivatives as BCR–ABL kinase inhibitors
Bioorganic &amp; Medicinal Chemistry Letters 2016.0
Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCR–ABL kinase
Bioorganic &amp; Medicinal Chemistry Letters 2012.0
Synthesis and biological evaluation of novel aromatic-heterocyclic biphenyls as potent anti-leukemia agents
European Journal of Medicinal Chemistry 2015.0
Design, synthesis, and biological activity of phenyl-pyrazole derivatives as BCR–ABL kinase inhibitors
Bioorganic &amp; Medicinal Chemistry 2015.0
Hybrid compounds as new Bcr/Abl inhibitors
Bioorganic &amp; Medicinal Chemistry Letters 2011.0
Design, synthesis, and biological evaluation of trizole-based heteroaromatic derivatives as Bcr-Abl kinase inhibitors
European Journal of Medicinal Chemistry 2022.0
Discovery of novel Bcr–Abl inhibitors targeting myristoyl pocket and ATP site
Bioorganic &amp; Medicinal Chemistry 2014.0
Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors
Bioorganic &amp; Medicinal Chemistry Letters 2006.0
Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity
European Journal of Medicinal Chemistry 2020.0